| Primary |
| Onychomycosis |
47.5% |
| Product Used For Unknown Indication |
11.1% |
| Fungal Infection |
8.6% |
| Nail Infection |
6.2% |
| Drug Use For Unknown Indication |
4.9% |
| Tinea Pedis |
4.9% |
| Contraception |
2.5% |
| Fungal Skin Infection |
2.5% |
| Rash |
1.9% |
| Smoking Cessation Therapy |
1.9% |
| Hypertension |
1.2% |
| Lower Respiratory Tract Infection |
1.2% |
| Tinea Cruris |
1.2% |
| Analgesic Therapy |
0.6% |
| Atrial Fibrillation |
0.6% |
| Body Tinea |
0.6% |
| Dermatophytosis |
0.6% |
| Fungal Infection Of Nail |
0.6% |
| Gastrooesophageal Reflux Disease |
0.6% |
| Intertrigo Candida |
0.6% |
|
| Urticaria |
15.3% |
| Cutaneous Lupus Erythematosus |
9.7% |
| Weight Decreased |
8.3% |
| Congestive Cardiomyopathy |
6.9% |
| Ageusia |
5.6% |
| Metrorrhagia |
5.6% |
| Systemic Lupus Erythematosus |
5.6% |
| Colitis Microscopic |
4.2% |
| Paraesthesia |
4.2% |
| Pustular Psoriasis |
4.2% |
| Vasculitis |
4.2% |
| White Blood Cell Count Decreased |
4.2% |
| Acute Generalised Exanthematous Pustulosis |
2.8% |
| Anosmia |
2.8% |
| Cholestasis |
2.8% |
| Depression |
2.8% |
| Dermatitis Exfoliative |
2.8% |
| Dysgeusia |
2.8% |
| Hepatitis |
2.8% |
| Nausea |
2.8% |
|
| Secondary |
| Product Used For Unknown Indication |
22.0% |
| Onychomycosis |
9.8% |
| Fungal Skin Infection |
7.3% |
| Pain |
7.3% |
| Allergic Rash |
4.9% |
| Dermatitis Allergic |
4.9% |
| Fungal Infection |
4.9% |
| Kerion |
4.9% |
| Pyrexia |
4.9% |
| Rash |
4.9% |
| Analgesic Therapy |
2.4% |
| Contraception |
2.4% |
| Dyslipidaemia |
2.4% |
| Essential Hypertension |
2.4% |
| Hypercholesterolaemia |
2.4% |
| Thrombophlebitis |
2.4% |
| Tinea Pedis |
2.4% |
| Trichophyton Infection |
2.4% |
| Trichophytosis |
2.4% |
| Vertebral Foraminal Stenosis |
2.4% |
|
| Road Traffic Accident |
14.3% |
| Trichophytosis |
14.3% |
| Abortion Induced |
7.1% |
| Ageusia |
7.1% |
| Blood Pressure Increased |
7.1% |
| Contrast Media Allergy |
7.1% |
| Depression |
7.1% |
| Dysgeusia |
7.1% |
| Hepatitis Cholestatic |
7.1% |
| Platelet Count Decreased |
7.1% |
| Pruritus |
7.1% |
| Tinea Infection |
7.1% |
|
| Concomitant |
| Rheumatoid Arthritis |
22.5% |
| Drug Use For Unknown Indication |
19.5% |
| Product Used For Unknown Indication |
18.1% |
| Adverse Event |
5.0% |
| Prophylaxis |
3.7% |
| Essential Hypertension |
3.0% |
| Gastritis Prophylaxis |
3.0% |
| Tinea Infection |
3.0% |
| Tinea Pedis |
3.0% |
| Rectal Cancer |
2.7% |
| Constipation |
2.3% |
| Hypertension |
2.3% |
| Diabetes Mellitus |
2.0% |
| Insomnia |
2.0% |
| Anaemia |
1.3% |
| Plasma Cell Myeloma |
1.3% |
| Premedication |
1.3% |
| Proctalgia |
1.3% |
| Vitamin Supplementation |
1.3% |
| Atypical Mycobacterial Infection |
1.0% |
|
| Vertigo |
17.5% |
| Pneumonia |
15.0% |
| Dermal Cyst |
10.0% |
| Delirium |
7.5% |
| Abdominal Distension |
5.0% |
| Diabetes Mellitus |
5.0% |
| Tendon Rupture |
5.0% |
| Toxic Skin Eruption |
5.0% |
| Anaemia |
2.5% |
| Blood Cholesterol Increased |
2.5% |
| Cardiac Arrest |
2.5% |
| Cerebrovascular Accident |
2.5% |
| Death |
2.5% |
| Deep Vein Thrombosis |
2.5% |
| Depression |
2.5% |
| Device Expulsion |
2.5% |
| Disseminated Intravascular Coagulation |
2.5% |
| Dizziness |
2.5% |
| Drug Ineffective |
2.5% |
| Eosinophilic Pneumonia |
2.5% |
|
